LeonaBio, Inc. (LONA) - Total Liabilities
Based on the latest financial reports, LeonaBio, Inc. (LONA) has total liabilities worth $64.36 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore cash efficiency ratio of LeonaBio, Inc. to assess how effectively this company generates cash.
LeonaBio, Inc. - Total Liabilities Trend (2018–2025)
This chart illustrates how LeonaBio, Inc.'s total liabilities have evolved over time, based on quarterly financial data. Check LONA asset resilience ratio to evaluate the company's liquid asset resilience ratio.
LeonaBio, Inc. Competitors by Total Liabilities
The table below lists competitors of LeonaBio, Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
U-Best Polymer Industry Co Ltd
TWO:4714
|
Taiwan | NT$3.94 Billion |
|
Kapsch Traffic
VI:KTCG
|
Austria | €322.77 Million |
|
Orthex Oyj
HE:ORTHEX
|
Finland | €47.28 Million |
|
Daejoo Inc
KQ:003310
|
Korea | ₩26.38 Billion |
|
Investigator Resources Ltd
AU:IVR
|
Australia | AU$735.67K |
|
Artiva Biotherapeutics, Inc. Common Stock
NASDAQ:ARTV
|
USA | $19.64 Million |
|
GreenTree Hospitality Group Ltd
NYSE:GHG
|
USA | $3.45 Billion |
|
Curo Co Ltd
KO:015590
|
Korea | ₩87.19 Billion |
Liability Composition Analysis (2018–2025)
This chart breaks down LeonaBio, Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see LONA market cap.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.88 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.32 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.70 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how LeonaBio, Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for LeonaBio, Inc. (2018–2025)
The table below shows the annual total liabilities of LeonaBio, Inc. from 2018 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $64.36 Million | +361.77% |
| 2024-12-31 | $13.94 Million | -53.63% |
| 2023-12-31 | $30.06 Million | +30.59% |
| 2022-12-31 | $23.02 Million | +110.69% |
| 2021-12-31 | $10.92 Million | +106.85% |
| 2020-12-31 | $5.28 Million | -75.90% |
| 2019-12-31 | $21.91 Million | +10.55% |
| 2018-12-31 | $19.82 Million | -- |
About LeonaBio, Inc.
LeonaBio, Inc., clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its product pipeline includes ATH-1105 for the treatment of amyotrophic lateral sclerosis, which is in phase 1 clinical trial; ATH-1020 for the treatment of neurodegenerative diseases, which is phase 1 clinical trial, as well as early compounds whic… Read more